Back pain is the number one cause of disability in the world and more money is spent treating it than all forms of cancer combined. DiscGenics is developing a treatment that doesn’t just relieve the pain, but has the potential to cure its underlying cause. DiscGenics is a clinical stage biopharma company and it has an allogeneic cell therapy made with proprietary cells to treat adult lumbar disc degeneration. In a Phase I/II clinical trial, patients demonstrated a rapid, durable, and statistically significant reduction in pain with increased function and quality of life in just 12 weeks that was sustained for two years thanks to the treatment’s ability to regenerate disc cells. DiscGenics has completed the construction of its own GMP manufacturing facility and hopes to gain conditional marketing approval in Japan in 2023 with the U.S. following on. The company has a broad patent portfolio that includes method of use, identity, manufacture, and several trade secrets surrounding its GMP certified manufacturing facility in Salt Lake City, Utah.


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.